rTMS for Bipolar Disorder

(CircuitBD Trial)

This trial tests a non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS) for treating depression in individuals with bipolar disorder. The researchers aim to determine if rTMS can improve mood by targeting specific brain areas associated with mood changes. Participants will undergo two types of rTMS sessions: one with active magnetic pulses and another with sham (inactive) pulses. Suitable participants should have a diagnosis of bipolar disorder and experience moderate depression, with or without stable medication. As a Phase 4 trial, this research seeks to understand how the already FDA-approved and effective treatment benefits a broader range of patients.

A previous study demonstrated that repetitive transcranial magnetic stimulation (rTMS) is safe and well-tolerated for treating depression. This technique uses magnetic pulses to stimulate specific brain areas and is non-invasive, meaning it doesn't involve surgery or entering the body.

The FDA has already approved rTMS for treating depression, which reassures about its safety. Recipients of rTMS often report mild side effects like headaches or feeling lightheaded. These effects are usually temporary and subside after the session.

Repetitive Transcranial Magnetic Stimulation (rTMS) is unique because it offers a non-invasive approach to treating bipolar disorder by using magnetic fields to stimulate nerve cells in the brain. Unlike traditional treatments like mood stabilizers and antipsychotic medications, which can take weeks to show effectiveness and may have significant side effects, rTMS has the potential to quickly alleviate symptoms with fewer side effects. Researchers are excited about this treatment because it targets brain activity directly, which could offer a new way to manage bipolar disorder more efficiently and effectively.

Research has shown that repetitive transcranial magnetic stimulation (rTMS) can help reduce symptoms of bipolar depression. Studies have found that targeting specific brain areas with rTMS can lessen depressive symptoms in individuals with bipolar disorder. For example, one review found rTMS effective when aimed at the R-DLPFC brain area. Another study noted improvements in 35% of patients with bipolar depression who did not respond well to medication. Additionally, real-world data supports that rTMS is helpful and well-tolerated for treating bipolar depression. In this trial, participants will receive either active rTMS followed by sham rTMS or sham rTMS followed by active rTMS, allowing researchers to evaluate the effectiveness of rTMS in managing bipolar depression. Overall, these findings suggest that rTMS could be a promising option for managing bipolar depression.⁶⁷⁸⁹¹⁰